Autopsy report · NCT03918447

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Discontinuation of all bardoxolone chronic kidney disease programs”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 4 years 2 months before it stopped.
667 participants enrolled.
Results were posted on the registry 10 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Biogen
Sponsor type: Industry
Conditions: Autosomal Dominant Polycystic Kidney; ADPKD
Interventions: Bardoxolone methyl oral capsule; Placebo oral capsule
Participants: 667
Sites: 137
Countries: Australia, Belgium, Czechia, France, Germany, Italy, Japan, Spain, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.